Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 1/2015

01-04-2015 | short review

Optimal follow-up of endometrial cancer patients

Authors: Eduard Vrdoljak, MD, PhD, Tihana Boraska Jelavić, MD, PhD, Branka Petrić Miše, MD, PhD

Published in: memo - Magazine of European Medical Oncology | Issue 1/2015

Login to get access

Abstract

Gynecological malignancies account round 10 % of all female cancers, with the uterine cancer being the most predominant one. Surveillance programs of all gynecologic cancers are primarily based on recurrence rates, timing of recurrence, salvage options and chances for cure of patient with recurrence. Since there is no prospective, high evidence data about optimal surveillance program after primary treatment of patients with endometrial cancer recommendations are based on review of retrospective data sets. From all the diagnostic tools available, history taking and clinical examination, including comprehensive gynecological examination, still contribute to the greatest number of recurrence detection. Radiologic tests are usually employed when a suspicion of recurrence is raised. Follow-up plan should be tailored according to the estimated risk of relapse for individual patient.
Literature
1.
Creutzberg CL, van Putten WLJ, Koper PCM, et al. for the PORTEC Study Group. Surgery and radiotherapy versus surgery alone for patients with stage –1 endometrial carcinoma: multicentre randomised trial. Lancet. 2000;355:1404–11.CrossRefPubMed
2.
Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.CrossRefPubMed
3.
Nout RA, Smit VTHBM, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.CrossRefPubMed
4.
Ben Arie A, Lavie O, Gdalevich M, et al. Temporal pattern of recurrence of stage I endometrial cancer in relation to histological risk factors. Eur J Surg Oncol. 2012;38(2):166–9.CrossRefPubMed
5.
Simpkins F, Papadia A, Kunos C, et al. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular invasion. Int J Gynecol Cancer. 2013;23(1):98–104.CrossRefPubMed
6.
Fung-Kee-Fung M, Dodge J, Elit L, et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol. 2006;101:520–9.CrossRefPubMed
7.
Milgrom SA, Kollmeier MA, Abu-Rustum NR, O’Cearbhaill RE, Barakat RR, Alektiar KM. Quantifying the risk of recurrence and death in stage III (FIGO 2009) endometrial cancer. Gynecol Oncol 2014;134:297–301. http://​dx.​doi.​org/​10.​1016/​j.​ygyno.​ Accesssed: 13 May 2014.CrossRefPubMed
8.
9.
Ayeni TA, Bakkum-Gamez JN, Mariani A, et al. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol. 2013;129:478–85.CrossRefPubMed
10.
Sartori E, Pasinetti B, Chiudinelli F, et al. Surveillance procedures for patients treated for endometrial cancer: a review of the literature. In J Gynecol Cancer. 2010;20(6):985–92.CrossRef
11.
Sartori E, Lafare B, Gadducci a, et al. Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Task Force (CTF) study. Int J Gynecol Cancer. 2003;13:458–65.CrossRefPubMed
12.
Moschiano EJ, Barbuto DA, Walsh C, et al. Risk factors for recurrence and prognosis of low-grade endometrial adenocarcinoma; vaginal versus other sites. Int J Gynecol Pathol. 2014;33:268–73.CrossRefPubMed
13.
Gaducci A, Cosio S, Fanucci A, Cristofani R, Genazzani AR. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. Anticancer Res. 2000;20:1977–84.
14.
Salani R, Backes FJ, Fung Kee Fung M Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011;204:466–78.CrossRefPubMed
15.
Smith CJ, Heeren M, Nicklin JL, et al. Efficacy of routine follow-up in patients with recurrent uterine cancer. Gynecol Oncol. 2007;107:124–9.CrossRefPubMed
16.
Tjalma WAA, Van Dam PA, Makar AP, Cruickshank DJ. The clinical value and the coseffectiveness of follow-up in endometrial cancer patients. Int J Gynecol Cancer. 2004;14:931–7.CrossRefPubMed
17.
Aung L, Howells RE, Lim KC, Hudson E, Jones PW. Why routine clinical follow-up for patients with early stage endometrial cancer is not always necessary: a study on women in South Wales. Int J Gynecol Cancer. 2014;24:556–63.CrossRefPubMed
18.
Zakhour M, Li AJ, Walsh CS, Cass I, Karlan BY, Rimel BJ. Post treatment surveillance of type II endometrial cancer patients. Gynecol Oncol. 2013;131(3):609–12.CrossRefPubMed
19.
Carrara L, Gadducci A, Landoni F, et al. Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis. Int J Gynecol Cancer. 2012;22(6):1013–9.CrossRefPubMed
20.
Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):33–8.
21.
Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. Can Med Assoc. 1997;157:879–86.
22.
Bristow RE, Purinton SC, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL 2nd. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol. 2006;103:709–13.CrossRefPubMed
23.
Kew FM, Roberts AP, Cruickshank DJ. The role of routine follow-up after gynecological malignancy. Int J Gynecol Cancer. 2005;15:413–9.CrossRefPubMed
24.
Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol. 2000;95:692–6.CrossRefPubMed
25.
Kadkhodayan S, Shahriari S, Treglia G, Yousefi Z, Sadeghi R. Accuracy of 18-F-FDG PET imaging in the follow-up of endometrial cancer patients: systematic review and meta-analysis of the literature. Gynecol Oncol. 2013;128(2):397–404.CrossRefPubMed
26.
Ozcan Kara P, Kara T, Kaya Bm Kara Gedik G, Sari O. The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: a comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker. Rev Esp Med Nucl Imagen Mol. 2012;31(5):257–60.PubMed
27.
Kitajima K, Suzuki K, Nakamoto Y, et al. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence. Eur J Radiol. 2012;81:3557–62.CrossRefPubMed
28.
Testa AC, Legge A D, Virgilio B, et al. Which imaging technique should we use in the follow-up of gynaecological cancer? Best Pract Res Clin Obstet Gynaecol 2014;28:769–91CrossRefPubMed
29.
Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L, Nelson BE. Serial serum Ca 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol. 1994;84:12–6.PubMed
30.
Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother. 2004;58(1):24–38.CrossRefPubMed
Metadata
Title
Optimal follow-up of endometrial cancer patients
Authors
Eduard Vrdoljak, MD, PhD
Tihana Boraska Jelavić, MD, PhD
Branka Petrić Miše, MD, PhD
Publication date
01-04-2015
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2015
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0202-z

Other articles of this Issue 1/2015

memo - Magazine of European Medical Oncology 1/2015 Go to the issue

short review

PET in lymphoma: who, when, how often, pitfalls?

short review

Clinical update: B-cell receptor kinase inhibitors in chronic lymphocytic leukemia

original report

New drugs on the horizon. Treatment of myeloma in 2020, a perspective

review

Radiotherapy for brain metastases: are we getting better?

short review

Tailoring treatment in myeloma: are there clues from biology?

case report

High-dose chemotherapy and autologous hematopoietic stem cell transplantation in a myeloma patient with terminal renal failure and hepatitis C with high viral load
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits